This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m 2 administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive non-Hodgkin's lymphoma. Patients were divided into two cohorts: those with non-cutaneous peripheral T-cell lymphoma (n=34) and those with other lymphomas (n=33). Efficacy was evaluated using the International Working Group criteria (1999). Of the 29 evaluable patients with non-cutaneous peripheral T-cell lymphoma, six had a response (overall response rate 20.7%; 95% confidence interval, 8.0%-39.7%), including two complete responses and four partial responses. No responses occurred in the 30 evaluable patients with other lymphomas (including 27 B-cell lymphomas). The most common plitidepsin-related adverse events were nausea, fatigue and myalgia (grade 3 in <10% of cases). Severe laboratory abnormalities (lymphopenia, anemia, thrombocytopenia, and increased levels of transaminase and creatine phosphokinase) were transient and easily managed by plitidepsin dose adjustments. The pharmacokinetic profile did not differ from that previously reported in patients with solid tumors. In conclusion, plitidepsin monotherapy has clinical activity in relapsed/refractory T-cell lymphomas. Combinations of plitidepsin with other chemotherapeutic drugs deserve further evaluation in patients with non-cutaneous peripheral 
Introduction
Non-Hodgkin's lymphomas (NHL) are a group of lymphoid neoplasms that rank among the ten most common types of cancer. There were an estimated 65,540 newly diagnosed cases and ~19,500 deaths from this malignancy in the United States in 2010. 1 In the European Union, about 74,000 new cases were diagnosed and ~31,000 patients died due to the disease in 2008. 2 Most NHL (85-90%) are precursor or mature B-cell lymphomas, whereas the remaining 10-15% are precursor or mature T-cell lymphomas. Over the last decade, there have been improvements in the outcome and survival of patients with B-cell NHL, as a result of increasing the doses of active cytotoxic drugs and adding the anti-CD20 monoclonal antibody rituximab to chemotherapy. 3 In contrast, peripheral T-cell lymphomas (PTCL) are still associated with poorer response rates and prognosis compared to B-cell lymphoma. 4, 5 The median overall survival of PTCL patients after anthracycline-based chemotherapy ranges between 20 and 34 months, with a 4-to 5-year overall survival rate between 28% and 38%. [6] [7] [8] Hence, new compounds for treating relapsed aggressive NHL, especially PTCL, constitute a truly unmet medical need.
Plitidepsin is a cyclic depsipeptide originally isolated from the Mediterranean tunicate Aplidium albicans and currently produced by chemical synthesis. Plitidepsin has shown activity against several human malignant cell lines, including leukemias 9, 10 and lymphoma. 11 Previous phase I studies showed that a plitidepsin schedule of 1-hour intravenous (i.v.) infusions given weekly on days 1, 8 and 15 every 4 weeks was the most convenient for patients with NHL. In addition, 3.2 mg/m 2 was defined as the recommended dose for phase II studies with this schedule. 12 The objective of this phase II clinical trial was to evaluate the efficacy, safety and pharmacokinetics (PK) of plitidepsin given at this dose and schedule to adult patients with relapsed or refractory aggressive NHL.
Eligibility criteria
Eligibility criteria included: relapsed or refractory, histologically confirmed aggressive NHL, with measurable disease (a bidimensional lesion >2 cm in its longer diameter or >5x10 9 /L lymphoma cells circulating in the peripheral blood); recovery from any non-hematologic toxicities derived from previous therapies; Eastern Cooperative Oncology Group performance status score of 0-2; normal left ventricular ejection fraction; and adequate hematologic, renal, and hepatic function.
Exclusion criteria included: acute lymphoblastic leukemia; central nervous system lymphoma; human immunodeficiency virusassociated lymphoma; concomitant treatment with any anti-proliferative drug; prior doxorubicin at cumulative doses >400 mg/m 2 , gene therapy with viral vectors, and/or mediastinal radiotherapy; more than three previous lines of systemic biological agents or chemotherapies; radiation, radionuclide therapy, surgery or immunosuppressive therapy within 4 weeks; nitrosoureas, high-dose chemotherapy or extensive beam radiation therapy within 6 weeks; other chemotherapies or biological agents within 3 weeks; other investigational product within 30 days; history of neoplastic disease (except for non-melanoma skin cancer, carcinoma in situ, or any other cancer curatively treated and with no evidence of disease for >10 years); history of significant neurological or psychiatric disorders; and other relevant diseases and medical conditions (e.g., unstable angina, myocardial infarction, valvular heart disease or congestive heart failure, symptomatic arrhythmia, uncontrolled arterial hypertension despite optimal therapy, abnormal electrocardiogram, active infection, significant non-neoplastic liver disease, and uncontrolled endocrine disease). Patients also had to use appropriate contraceptive measures.
Study treatment
Plitidepsin (PharmaMar, Colmenar Viejo, Madrid, Spain) was administered through a central or peripheral venous line as a 1-hour infusion at a dose of 3.2 mg/m 2 weekly on days 1, 8 and 15 every 4 weeks. Prophylactic premedication consisted of glucocorticoids (dexamethasone 8 mg i.v.), 5-HT3 antagonists (ondansetron or equivalent), an H 1 -receptor antagonist (diphenhydramine hydrochloride 25 mg i.v. or equivalent) and an H 2 -receptor antagonist (ranitidine 50 mg i.v.). Therapeutic use of hematopoietic colony-stimulating factors was allowed. No other antineoplastic therapy was permitted (except for pain management, imminent bone fractures or spinal cord compression). Plitidepsin was administered until progressive disease, clinical deterioration, or unacceptable toxicity.
Two dose reductions, at most, were allowed for the following adverse events: febrile neutropenia; grade 4 neutropenia lasting >5 days; grade 3/4 thrombocytopenia; grade 3/4 nausea/vomiting despite adequate prophylaxis; grade ≥2 increase in bilirubin; grade 3/4 increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST); grade 3/4 increase in alkaline phosphatase; grade ≥2 muscular toxicity [creatine phosphokinase (CPK) increase, myalgia and/or muscular weakness]; or any other grade 3/4 non-hematologic toxicity.
Efficacy assessment
Efficacy was assessed every 8 weeks using magnetic resonance imaging or computed tomography. Treated patients who had at least one disease assessment were considered evaluable for efficacy. The primary efficacy endpoint was the best overall response rate, defined as the combined rate of complete response, unconfirmed complete response and partial response according to the International Working Group criteria for NHL. 13 Time-to-event endpoints were secondary efficacy endpoints.
Safety assessment
All patients who received at least part of one plitidepsin infusion were considered evaluable for safety. Adverse events were graded according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), v. 3.0. Safety was evaluated throughout the study and for up to 30 days after administration of the last dose of plitidepsin, and all patients were followed until recovery from any drug-related adverse events.
Statistical methods
Sample size was based on the primary endpoint (overall response rate). A Simon's two-stage design 14 was adopted to test the null hypothesis that P≤0.10 versus the alternative that P≥0.25. The expected sample size was 40 patients. Sixteen patients were to be enrolled in the first stage, regardless of their type of lymphoma. The study was to be terminated due to lack of efficacy if no responses occurred in this stage. If at least one response occurred, the study was to continue until the expected total of 40 evaluable patients had been accrued.
After the accrual of 42 evaluable patients with relapsed/refractory lymphoma of any type (including 12 PTCL without cutaneous lymphoma), an extension cohort of 16 patients with noncutaneous PTCL was recruited. Hence, expected accrual was 58 evaluable patients, 28 of whom with non-cutaneous PTCL. If ≥7 of these 28 patients were responders, the hypothesis that P≥0.350 for non-cutaneous PTCL was to be rejected (b=0.182) and this schedule would no longer be evaluated in this setting. Otherwise, if ≥8 non-cutaneous PTCL patients were responders (i.e., an overall response rate of 28.6%), the null hypothesis P≥0.150 would be rejected (α=0.049) and the plitidepsin schedule would be considered promising in this indication.
Statistical analyses
Both efficacy and safety analyses were conducted separately for the cohort of patients with non-cutaneous PTCL and for the cohort of patients treated for other lymphomas. The primary endpoint (overall response rate) was calculated using descriptive statistics (95% confidence interval and range). Time to progression, time to subsequent chemotherapy, progression-free survival and overall survival were analyzed by the Kaplan-Meier method. Time to response onset and duration of response were analyzed by calculating the median and range of values.
Pharmacokinetic analyses
Blood samples (5 mL) for PK evaluation were collected at predefined times at the first plitidepsin infusions (0, 0.5-0.83, 1.42-2, 3-4, 5.5-8.5, 20-33 and 168 hours after the start of the infusion) from patients recruited into the second stage of the study (i.e., excluding the 16 patients recruited into the first stage, regardless of lymphoma type). Blood samples were taken from the arm not receiving the infusion. A 3-mL aliquot of whole blood was stored at -20ºC. Whole blood concentrations of plitidepsin were determined using a validated high performance liquid chromatography system coupled with electrospray ionization tandem mass spectrometry (HPLC-MS/MS) method. 15 Complete concentration-time profiles of plitidepsin were analyzed by standard non-compartmental methods.
Results

Patients' characteristics
Non-cutaneous peripheral T-cell lymphomas
Thirty-four patients were enrolled (Table 1) . Twenty-three (67.6%) had stage III-IV disease at diagnosis. All had refractory (n=18, 52.9%) or relapsed (n=16, 47.1%) disease at baseline, 16 (47.1%) had extranodal disease and seven (20.6%) had bone marrow involvement. All patients had received prior systemic therapy, with a median of two lines (range, 1-5 lines) per patient. Other prior therapies comprised radiotherapy (n=8, 23.5%) and stem cell transplantation (n=9, 26.5%).
Other lymphomas
Thirty-three patients were included in this cohort (Table  1) . Twenty-four (72.7%) had stage III-IV disease at diagnosis. Most (n=24, 72.7%) had refractory disease at baseline, while the other nine (27.3%) had relapsed disease. Eighteen (54.5%) had extranodal disease and seven (21.2%) had bone marrow involvement. Prior systemic therapy was given to all patients, with a median of three lines (range, 1-10 lines) per patient. In addition, prior radiotherapy was given to 11 patients (33.3%) and seven underwent stem cell transplantation (21.2%).
Treatment and dosing
Non-cutaneous peripheral T-cell lymphomas
A total of 77 plitidepsin cycles were administered, with a median of two cycles per patient (range, 1-8 cycles). The median relative dose intensity was 87.4%. Most patients (n=21; 65.6%) discontinued the study treatment due to disease progression (Figure 1 ).
Other lymphomas
A total of 57 plitidepsin cycles were administered, with a median of 1.5 cycles per patient (range, 1-4 cycles). The median relative dose intensity was 94.6%. Most patients (n=28; 87.5%) discontinued the study treatment due to disease progression (Figure 1 ).
Efficacy
Three patients with non-cutaneous PTCL and two with other lymphomas were excluded from the efficacy analysis ( Figure 1 ). The reasons for exclusion were no tumor evaluations during treatment (n=2); lesions not measurable according to International Working Group criteria; having an active infection at study entry; and wrong diagnosis (lung carcinoma instead of aggressive NHL) (n=1 each). Figure 2 shows a waterfall chart of the changes in tumor size that occurred in 32 patients with bidimensional measurements taken from the same lesions at baseline and during treatment with plitidepsin: 16 with non-cutaneous PTCL and 16 with other lymphomas.
Non-cutaneous peripheral T-cell lymphomas
Six patients showed an objective response to plitidepsin (two complete responses and four partial responses; overall response rate = 20.7%, 95% CI, 8.0%-39.7%) ( Table 2 ). The histologies of the six responding patients comprised angioimmunoblastic T-cell lymphoma (n=3, including both patients with complete responses) and PTCL (n=3). Both patients who achieved a complete response had previously received high-dose therapy and stem cell transplantation: one received eight cycles and achieved longterm remission (lasting for 27.9 months), and the other one showed a bone marrow complete morphological remission for 2.8 months. The median duration of response was 2.2 months (range, 0-27.9 months), with the response lasting for >14 weeks in two patients (6.9%); one patient with partial response developed septic shock unrelated to treatment shortly after a response had been documented and was withdrawn from the study. In addition, six patients had disease stabilization. The median time to progression was 1.6 months (95% CI, 1.1-3.0 months), the median progression-free survival was 1.6 months (95% CI, 1.1-2.7 months), and the median overall survival was 10.2 months (95% CI, 4.4-24.3 months) . The time to progression was ≥3 months in six patients.
Other lymphomas
None of these patients responded to plitidepsin ( Table  2 ). The median time to progression/progression-free sur- vival was 1.3 months (95% CI, 0.8-1.6 months), and the median overall survival was 4.5 months (95% CI, 2.7-6.4 months).
Safety
Most treatment-related adverse events were mild/moderate (Table 3 ). The most common were nausea, fatigue and myalgia. Seven patients had grade 3/4 treatment-related adverse events. These comprised muscle weakness (n=2), Guillain-Barré syndrome, increased cardiac troponin I, decreased ejection fraction (all three with an unknown relationship to treatment), prolonged QTc interval on an electrocardiogram, supraventricular arrhythmia, tachycardia, myalgia, back pain, injection site reaction, fatigue and edema (n=1 each).
The most common severe hematologic abnormalities were grade 3 anemia and grade 3/4 lymphopenia ( Table 3 ). All patients with severe anemia and most of those with severe neutropenia or thrombocytopenia already had these abnormalities at baseline. No cases of febrile neutropenia were found. Most severe biochemical abnormalities did not reach grade 4. The most common were grade 3 increases in ALT/AST and grade 3/4 increases in CPK; all these abnormalities were transient and were managed with dose delays, omissions or reductions, and none resulted in treatment discontinuation. Other severe biochemical abnormalities were less common and had no effects on treatment. Of note, three patients with ALT/AST increases and all those with severe increases in alkaline phosphatase or bilirubin levels while on plitidepsin already showed these abnormalities at baseline. Five patients were withdrawn from the study due to treatment-related adverse events: grade 2 CPK increase (n=2); maculo-papular rash; a combination of hypotension, rigors, injection site reaction and back pain; and asthenia concomitant with muscular toxicity (n=1 each).
Pharmacokinetics
A total of 23 patients had evaluable PK profiles, and 19 of them had a complete profile (with samples up to 168 hours) after the start of the first plitidepsin infusion. The PK profile of plitidepsin in NHL patients was characterized by a mean clearance of 7.45 L/h, a mean volume of distribution at steady state (V ss ) of 355 L and a mean terminal half-life of 36.5 h. A population PK model consisting of an open, three-compartment model with linear elimination and distribution from the central compartment was appropriate to describe the time course of i.v. plitidepsin whole blood concentrations in NHL patients. Univariate analyses found statistically significant direct relationships of plitidepsin whole blood clearance with baseline hemoglobin, albumin, b 2 -microglobulin, body surface area, body weight and serum creatinine; and of whole blood V ss with baseline hemoglobin, serum albumin, body surface area, creatinine and body weight. In the multivariate analysis, hemoglobin was the only parameter to retain a statistically significant influence, although its significance disappeared when serum albumin was added to the model.
Discussion
This exploratory phase II clinical trial was designed to evaluate the efficacy, tolerability and PK of plitidepsin at a dose of 3.2 mg/m 2 as a 1-hour infusion given on days 1, 8 and 15 every 4 weeks to adult patients with histologically confirmed aggressive NHL that had relapsed after standard or high-dose chemotherapy, or that was refractory to its more recent chemotherapy. This schedule was evaluated in two cohorts: patients with non-cutaneous PTCL and patients with other lymphomas. PTCL is a heterogeneous form of NHL that is generally associated with a poor clinical outcome. Several drugs have been evaluated as single agents in phase II trials for PTCL (Table 4) . Some (e.g., the anti-CD52 monoclonal antibody alemtuzumab or the purine nucleoside nelarabine) have shown antitumor activity for this indication but have been associated with significant and unacceptable toxicity and their development has, therefore, been discontinued. 16, 17 In other cases (e.g., bortezomib, gemcitabine, lenalidomide, denileukin diftitox, romidepsin, and zanolimumab), overall response rates ranging between 24% and 55% and good safety profiles have been found, but the data currently available are still inconclusive and need to be confirmed in further clinical trials. [18] [19] [20] [21] [22] [23] Finally, weekly administration of the antifolate pralatrexate for 6 weeks in 7-week cycles produced an overall response rate of 27% in adults with relapsed/refractory PTCL (with 12% of response lasting >14 weeks) while showing a toxicity profile similar to that of other antifolates. These results were considered as likely predictive of clinical benefit, and in 2009 pralatrexate was granted accelerated approval for the treatment of relapsed/refractory PTCL. 24 To date, no other drug has been approved for this indication.
In the cohort of patients with non-cutaneous PTCL, the overall response rate to plitidepsin of 20.7% in this phase II trial was lower than the 28.6% pre-established by the study protocol to consider this schedule worthy of further evaluation. However, the finding of two complete responses in patients who had been pretreated with stem cell transplantation, which in one case was long-lasting (more than 27 months) and in the other case included complete bone marrow remission for 2.8 months, suggests that plitidepsin may have a role in the management of non-cutaneous PTCL in combination with other chemotherapeutic drugs. The short median duration of response (2.2 months) achieved in this cohort is not surprising, given that the patients were heavily pretreated (median of 1.5 lines per patient). Of note, the dose of prophylactic dexamethasone given to these patients (8 mg weekly) was low and unlikely to explain this antitumor A preclinical study showed that plitidepsin combined with the cell cycle blocker gemcitabine was generally more effective than either drug alone. 25 A phase I clinical trial is currently evaluating this plitidepsin schedule combined with gemcitabine in mature non-cutaneous T-cell lymphomas.
No responses were found in the cohort with other lymphomas and, therefore, further evaluation of this plitidepsin schedule in patients with relapsed/refractory Bcell lymphomas or T-cell lymphomas other than non-cutaneous PTCL is not warranted.
Plitidepsin was generally well tolerated and showed manageable toxicity when given to patients with relapsed/refractory NHL. Most plitidepsin-related adverse events were mild or moderate. The most common were nausea, fatigue and myalgia. The most common severe hematologic abnormalities were grade 3 anemia and grade 3/4 lymphopenia, while the most common severe biochemical abnormalities were grade 3 ALT/AST and grade 3/4 CPK increases. These abnormalities were transient and were mostly managed by dosing delay, omission or reduction. The overall safety profile was in accordance with that reported in a previous phase I clinical trial with this single-agent schedule in patients with solid tumors. 12 Of note, many of the side effects commonly induced by cytotoxic agents, such as alopecia, mucositis/stomatitis or clinically relevant myelosuppression, were not characteristic of plitidepsin.
The PK profile of plitidepsin in NHL patients was similar to that found in patients treated with the same dose and schedule in a phase I study of patients with solid tumors. 12 The time course of plitidepsin whole blood concentrations in NHL patients was appropriately described by an open,
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haematologica | 2013; 98(3) Table 4 . Results of chemotherapeutic agents tested as single-agent therapies in phase II trials that included patients with relapsed/refractory peripheral T-cell lymphoma.
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Study
Drug/schedule and dose N. of patients with PTCL Responses in PTCL ORR Types of response (%) three-compartment population PK model with linear elimination and distribution from the central compartment, and a non-linear distribution to blood cells. This same model was defined for plitidepsin in a population PK meta-analysis of data from 283 patients with advanced solid tumors who received the drug as monotherapy at doses ranging from 0.13 to 8.0 mg/m 2 and at different schedules, one of which was the one evaluated in the present study. 26 In conclusion, single-agent plitidepsin has shown antitumor activity and a tolerable safety profile in patients with relapsed/refractory non-cutaneous PTCL. These results therefore support the conduct of further clinical trials to evaluate plitidepsin-containing combined therapies in this disease setting. 
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